바이오인

출처 : 영국 과학기술청(office for Life Sciences)

영국 생명과학 경쟁력 지표

Life Science Competitiveness Indicators

● Introduction

This Office for Life Sciences (OLS) report brings together international comparisons of a set of indicators on the competitiveness of the life science environment in the UK. It is the second time OLS have published this report. It complements the other annual
OLS publication ? Strength & Opportunity ? which provides a more detailed analysis of the life science industry landscape in the UK only.

Improvements made since the 2015 publication include:
? Adding narrative text to describe trends
? Incorporating supplementary data into the narrative in some cases to support up to date understanding of the UK position
? Publishing a spreadsheet with underlying data for the majority of indicators (where data is from a proprietary source this has not been possible).

As with most internationally comparable data, it takes time for the data to be collated and updated. In some cases we have used UK specific data to provide a more up-to-date picture of the UK position. Internationally comparable data limitations mean that, while this is the most complete picture we can provide, the set of indicators cannot be looked at in aggregate to provide an overall country ranking. Each indicator should be considered individually.

The data is mostly sourced from published data sets. The web links and caveats are provided where this is the case, along with the data in the accompanying spreadsheet. In a few instances, it has been necessary for data to be sourced commercially or
obtained directly from the organisation holding it. In these cases, the supplier is clearly credited against relevant charts. In cases where the data is from a proprietary source, we have not been able to reproduce the underlying data tables.

The choice of indicators was informed by engagement with life science sector stakeholders, including trade associations, life science companies, research organisations, regulators and government bodies. We have ed comparator countries on
advice from stakeholders, however, in some cases this choice has been limited by data availability.

We would like to thanks all of those who have contributed to the development of this report.

 ● Table of contents

Overview: Performance of UK Life Science Sector and
Contribution to UK Economy

Overview: Competitiveness of UK Life Science Environment

Indicators for UK industry
Chart 1A: Number of people employed in manufacture
of basic pharmaceutical products and pharmaceutical preparations

Chart 1B: Number of people employed in manufacture
of medical technology products

Chart 2: Gross Value Added for pharmaceutical manufacturing

Chart 3A: Exports of medical technology products

Chart 3B: Exports of medical technology products

Chart 4A: Imports of pharmaceutical products

Chart 4B: Imports of medical technology products

Chart 5A: Life sciences foreign direct investment projects

Chart 5B: Life sciences foreign direct investment ? capital expenditure

Chart 6A: Share of global life science Initial Public Offerings (IPOs) ? 2015

Chart 6B: Initial Public Offerings (IPOs) in life sciences
? amount raised in 2015 (where known)

Chart 7A: Private equity investment ? total investment

Chart 7B: Number of companies receiving private equity investment

Chart 8: Number of science graduates

Research and Development Indicators
Chart 9: Government spend on health research and development

Chart 10: 2014 non-industry spend on research and development

Chart 11: Pharmaceutical industry spend on research
and development in the UK

Chart 12A: Share of life science academic citations

Chart 12B: Share of top 1% (most cited) life science citations

Regulatory Indicator
Chart 13: Instances where MHRA is in lead role in
EU regulatory procedure

Clinical Research Indicators
Chart 14: Share of patients recruited to global studies (all trial phases)

Chart 15: Time from core package received to first patient enrolled in
country (all trial phases)

Demand-side Indicators
Chart 16: Dashboard of NICE Technology Appraisal publication

Uptake of New Medicines

Chart 17A: Uptake of new medicines ? NICE approved

Chart 17B: Uptake of new medicines ? non-NICE approved

...................(계속)

☞ 자세한 내용은 내용바로가기 또는 첨부파일을 이용하시기 바랍니다.